Kopran Ltd

Kopran Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, recorded a fresh 52-week low of Rs.115.65 today, marking a significant decline amid a sustained downward trend. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures on its financial performance and valuation metrics.

Kopran Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 25 February 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 10 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Kopran Ltd’s shares declined to a fresh 52-week low of Rs.115.75 on 9 Mar 2026, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical company’s stock has underperformed both its sector and the broader market, reflecting persistent challenges in financial performance and market sentiment.

Kopran Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, with recent indicators signalling a transition from mildly bearish to a more pronounced bearish trend. Despite some mildly bullish signals on weekly MACD and KST, the overall technical landscape remains challenging, reflecting in the company’s downgraded Mojo Grade to Strong Sell and a significant price decline in early March 2026.

Kopran Ltd, a Pharmaceuticals & Biotechnology micro-cap, has exhibited a nuanced shift in technical momentum as recent data reveals a transition from a strongly bearish stance to a mildly bearish trend. Despite a modest 2.5% gain in the latest session, the company’s technical indicators present a mixed picture, underscoring the challenges faced in reversing longer-term downtrends amid sectoral headwinds and broader market dynamics.

Kopran Ltd, a player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Sell to a Strong Sell rating by MarketsMOJO as of 25 Feb 2026. This revision reflects deteriorating financial performance, bearish technical indicators, and subdued valuation metrics, signalling heightened caution for investors amid ongoing challenges.

Kopran Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, with recent indicators signalling a transition from mildly bearish to a more pronounced bearish trend. Despite a modest day gain of 0.86%, the stock’s broader technical landscape and fundamental metrics suggest caution for investors amid sector headwinds and underperformance relative to the Sensex.

Kopran Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 04 February 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 16 February 2026, providing investors with the latest insights into its performance and outlook.

Kopran Ltd’s investment rating has been upgraded from Strong Sell to Sell as of 4 February 2026, driven primarily by a shift in technical indicators despite ongoing financial challenges. The company’s Mojo Score now stands at 34.0, reflecting a cautious but slightly improved outlook amid persistent operational headwinds and valuation considerations.

Kopran Ltd has exhibited a notable shift in its technical momentum, moving from a strongly bearish stance to a mildly bearish trend, reflecting a nuanced change in investor sentiment. Despite a 3.46% gain in the latest session, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages, and other momentum oscillators, underscoring the challenges faced by this Pharmaceuticals & Biotechnology player in the current market environment.

Kopran Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 20 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 02 February 2026, providing investors with the most up-to-date view of the company’s performance and outlook.

Kopran Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.123.2 today, marking a significant milestone in its ongoing price decline. The stock has underperformed its sector and broader market indices, reflecting persistent challenges in its financial performance and market positioning.

Kopran Ltd’s latest quarterly results for December 2025 reveal a modest improvement in its financial trend, shifting from very negative to negative territory. Despite achieving record net sales and improved cash reserves, the pharmaceutical company continues to grapple with declining profitability and rising interest costs, underscoring persistent operational challenges in a competitive sector.

Kopran Limited, a Mumbai-based pharmaceutical manufacturer specialising in penicillin and non-penicillin-based drugs, reported net profit of ₹9.34 crores for Q3 FY26 (October-December 2025), marking a sharp reversal from the previous quarter's loss but representing a 10.19% year-on-year decline. The company's shares, trading at ₹135.75 on the National Stock Exchange, have witnessed a significant correction of 33.78% over the past year, substantially underperforming both the benchmark Sensex and the broader pharmaceuticals sector.

Kopran Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 20 Jan 2026. This shift reflects deteriorating technical indicators, disappointing financial trends, and concerns over valuation and quality metrics, signalling heightened caution for investors amid ongoing underperformance.